Back to search results

Addressing Genomic Disparities in Cancer Survivors

This study aims to improve genetic education and testing for hereditary cancer risk among Black cancer survivors. It compares two approaches: a "Relational Agent" (RA) chatbot, which provides genetic education and encourages testing, and "Enhanced Usual Care" (EUC), which involves a clinical letter recommending genetic testing. The study will see if the chatbot helps more people get genetic testing and understand its impact on their well-being. You may be able to join if you are a Black or African American cancer survivor, aged 18-80, who has not had genetic testing for hereditary cancer and received care at a participating site in the last five years. The study plans to enroll 428 participants.

Study design
This study is a randomized controlled trial with two groups, aiming to enroll 428 participants. Participants will be randomly assigned to either the Relational Agent (chatbot) group or the Enhanced Usual Care group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will assess the impact of the interventions at 1-month and 6-month surveys, and genetic testing uptake will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06073626

Addressing Genomic Disparities in Cancer Survivors

Recruiting
NAAges 18–80InterventionalHealth services
Rutgers, The State University of New Jersey
~428 participants
Updated 2025-10-28 on ClinicalTrials.gov
What's tested:Relational agent (RA) / ChatbotEnhanced Usual Care (EUC)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of Germline Genetic Testing
Measured over 6-months
+2 more outcomes measured

Conditions

Hereditary Cancer
Genetic Testing

Explore related trials

Breast CarcinomaColorectal CarcinomaMalignant Ovarian NeoplasmMalignant Uterine NeoplasmPancreatic CarcinomaProstate CarcinomaSolid Neoplasm

Where it's being run

2 sites across 2 states
District of Columbia1
New Jersey1

Study leadership

  • Anita Y Kinney, PhD, RN · PRINCIPAL_INVESTIGATOR · Director at Rutgers Cancer Institute

Who to contact

Erin Speiser, PhD, MA
[email protected]
732-675-1668
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-80 years of age
Self-identify as Black or African American
At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic
Have not had genetic testing for hereditary cancer
Have received care at one of the participating sites in the prior five years
Meet National Comprehensive Cancer Network criteria for germline GT
Able to read and speak in English
Capable of providing informed consent
Have internet access (via smartphone, tablet or computer)
Comfortable using a computer or mobile phone independently to access information

Exclusion

Do not speak English
Unable to access the Internet
Have previously undergone germline genetic testing for hereditary cancer risk or previously had genetic counseling (GC) and declined genetic testing (GT)
Are unable to provide informed consent

What this trial measures

  • Uptake of Germline Genetic Testing6-months

    As captured via internal RedCap form for the number or count of participants who opt for genetic testing, the investigators will test the efficacy of a culturally tailored and interactive electronic relational agent (RA) intervention vs. enhanced usual care (EUC) consisting of clinical letter and genetic recommendation on engagement in genetic testing uptake;

  • Survey Assessment of Impact of RA vs. EUC1-month and 6-month survey

    Evaluate the impact of the RA vs. EUC on informed decision-making and psychosocial outcomes via survey measures of related constructs at 1-month and 6-month surveys. Multiple scales are used to measure this outcome and each scale has a unique scoring system.

  • Survey Assessment of Mediators and Moderators of EfficacyBaseline, 1-month and 6-month surveys

    Explore potential mechanisms by assessing mediators and moderators of efficacy via survey measures of related constructs at baseline, 1-month and 6-month surveys. Multiple scales are used to measure this outcome and each scale has a unique scoring system.